How Much Does Tirzepatide Cost in 2026?

Tirzepatide cost at a glance: which price fits you

Start with the line that sounds like you.

• Cheapest way to start: compounded tirzepatide from Mochi Health, about $170 a month at the lowest dose, rising to about $280.
• No membership fee: Curex, from about $250 a month month to month, or about $200 on a prepaid year, with the visit and shipping included.
• Real Zepbound without insurance: LillyDirect, about $300 to $450 a month by dose.
• Your plan covers Zepbound: Lilly's savings card, as low as $25 a month.
• On Medicare Part D: the GLP-1 Bridge, $50 a month for the Zepbound KwikPen if you qualify.
• You have type 2 diabetes: Mounjaro through your insurance is often the cheapest route.

Compounded tirzepatide cost: about $170 to $450 a month through telehealth

For most people paying cash, compounded tirzepatide is still the cheapest route in 2026. A compounding pharmacy mixes it for you on a prescription. It is not FDA-approved as a finished product.

Prices vary more than the landing pages suggest. Check whether a membership comes on top. Check whether the quote is for the starter dose. Then ask how much the price climbs as your dose goes up.

Curex: one all-in price, no membership

Curex puts the medicine, the visit and shipping in one price, with no separate membership. That simplicity earns it our top spot.

The catch is its "from $199" headline. That price needs a year paid upfront, at the lowest dose. Month to month, the tablet costs about $250 and the shot about $300 at the starting dose. Both cost about $100 more at higher doses.

Mochi Health: the lowest starting price, plus a membership

Since August 15, 2026, Mochi prices tirzepatide by dose. The medicine runs about $90 a month at the lowest dose. At the top dose, it costs about $200. A $79 monthly membership comes on top of the medicine.

All-in, that is about $170 a month at the lowest dose and about $280 at the top dose. New members get the first month of membership free, so month one costs about $90. That offer is not available in every state. Mochi now lets you pick among partner pharmacies, so the medicine price can vary a little.

Henry Meds: tirzepatide tablets, one bundled bill

Henry Meds offers tirzepatide only as a pill, not an injection. The pill starts at about $350 a month, billed every 3 months.

Both prices include visits, supplies and shipping, with no membership fee. The pill is billed as a 3-month supply, about $1,045 at a time. Henry says its price varies with your dose, and it does not publish the higher-dose prices. It is not the cheapest start. The draw is the needle-free option and the simple bill.

Willow: from about $400 a month in 36 states

Willow charges about $400 a month all-in for compounded tirzepatide at the starting doses. The price rises with your dose, to about $550 a month at the top. There is no membership fee on top. Willow also sells a tirzepatide tablet that dissolves under the tongue, from about $400 a month. It is available in 36 states, so check yours before you start the intake.

A note on the legal footing for all four. The FDA declared the tirzepatide shortage over in December 2024. Mass compounding from the shortage years wound down in early 2025. What remains is narrower. A pharmacy can make it for one patient when a prescriber documents why she needs a custom version. Ask any provider which pharmacy fills your order and how your prescription is documented.

LillyDirect self-pay: the brand option that competes with compounded

In late 2024, Eli Lilly began selling Zepbound directly to people paying cash, at well under half the retail price. Today LillyDirect sells both the KwikPen and the single-dose vial at the same self-pay prices:

• 2.5mg starter dose: about $300 a month.
• 5mg: about $400 a month.
• 7.5mg up to 15mg: about $450 a month.

That makes LillyDirect the closest brand-name tirzepatide comes to compounded prices. It is the FDA-approved drug, shipped by the maker. Our tirzepatide dosage chart shows how fast you move through those doses, which tells you when the price steps up.

The fine print is a 45-day refill window from 7.5mg up. The clock starts at your last delivery. Miss it and a 7.5mg fill costs about $500, and higher doses about $700. Set a calendar reminder before your first delivery arrives.

• Pros: the FDA-approved drug, direct from Lilly; the starter dose is close to compounded prices; pen or vial at the same price.
• Cons: the 45-day refill rule is strict; higher doses still cost more than the cheapest compounded programs.
• How to get it: any US-licensed prescriber can send the prescription, or LillyDirect can connect you with an independent telehealth partner.
• At your local pharmacy: since March 2026, major retail pharmacies also sell the Zepbound KwikPen at these self-pay prices, with Lilly's free savings card.

Brand-name tirzepatide cost: Zepbound and Mounjaro at the pharmacy

Tirzepatide is sold under two brand names. Zepbound is FDA-approved for weight management. Mounjaro is FDA-approved for type 2 diabetes. The molecule is identical, but the price, the insurance rules and how doctors prescribe them differ.

Zepbound retail cost

Lilly's list price for Zepbound is about $1,085 a month, close to $13,000 a year. That is the maker's catalog price, known as WAC. Few people pay it.

A GoodRx coupon barely moves it, to about $995 to $1,050 a month depending on the pharmacy. Coupons can only trim a little off a brand still under patent. For an uninsured woman, the real floor is Lilly's self-pay price, at LillyDirect or a major pharmacy.

Mounjaro retail cost

Mounjaro's list price is about $1,110 a month per carton. With a GoodRx coupon it typically runs about $1,090, so again the coupon barely helps. If your work plan does not cover Mounjaro, Lilly's Mounjaro savings card can bring a month down to about $500, for an approved use. With no insurance at all, LillyDirect sells Mounjaro self-pay for about $500 at every dose. Zepbound self-pay costs less for the same molecule.

Because Mounjaro is approved for diabetes, not weight loss, prescribing it for weight alone is off-label. Some insurers cover it only with a diabetes diagnosis. If you have type 2 diabetes, Mounjaro through insurance is often the cheapest tirzepatide route of all.

Does insurance cover tirzepatide?

Insurance is the cheapest route for women who qualify. Zepbound is FDA-approved for three situations. The first is obesity, meaning a BMI of 30 or more. The second is a BMI of 27 or more with a weight-related condition such as high blood pressure. The third is moderate to severe obstructive sleep apnea with obesity.

Many commercial plans cover Zepbound in those cases, usually after a prior authorization, which is your insurer's approval step. If your plan covers it, Lilly's Zepbound savings card can bring your cost as low as $25 a month. The card pays at most $100 a month, so a higher copay leaves you more to pay. It does not work with Medicare or Medicaid.

Mounjaro follows different rules. Insurers typically cover it only with a type 2 diabetes diagnosis.

Medicare Part D, Medicare's drug coverage, has long excluded weight-loss drugs. Two exceptions now matter. Part D plans can cover Zepbound for sleep apnea. And since July 1, 2026, Medicare's GLP-1 Bridge gives eligible Part D members the Zepbound KwikPen for $50 a month. The Bridge runs through the end of 2027. For plans, appeals and the Bridge in detail, see tirzepatide cost with insurance.

• Check the right benefit: look up Zepbound under your plan's obesity or weight-management benefit, not just the drug list.
• Ask about the diagnosis codes: BMI alone is often not enough, and a related condition on the prior authorization can matter.
• Employer plans set their own rules: some large employers added GLP-1 obesity coverage in 2025 and 2026.
• If you are denied, appeal: send clinical notes and a letter from your doctor.

Annual tirzepatide cost: what each route costs per year

Monthly numbers hide the real decision. Here is the first-year cost of each route, following the usual dose steps where the price changes with the dose.

• With insurance and the savings card: as low as about $300 a year.
• Mochi Health: about $1,950 in the first year if you stay at the lowest dose, with the free first month. About $2,970 if you step up one dose a month to the top.
• Curex: about $2,390 for a year paid upfront at the lowest dose, about $3,590 at higher doses.
• Willow: about $4,790 a year on the starting doses, up to about $5,865 if you climb to 13.5 mg.
• Henry Meds: about $4,190 a year for the tablets, its only tirzepatide option.
• LillyDirect Zepbound: about $5,190 in the first year if you step up to 7.5mg or more. About $4,690 if you stay at 5mg.
• Zepbound with GoodRx: about $11,900 to $12,600 a year.
• Zepbound at full retail: about $13,000 a year.

Even the priciest compounded plan here, Willow at the top doses, saves more than $7,000 a year compared with full retail. One more trap: some providers bill every 28 days instead of monthly. That is 13 charges a year, which adds about 8% to any monthly figure.

Why tirzepatide matters for women in perimenopause and menopause

Weight gain in perimenopause is not just a willpower problem. As estrogen falls, fat shifts toward the belly, and strategies that used to work often stop working.

Tirzepatide acts on two gut hormone pathways, GLP-1 and GIP. Together they curb appetite, slow how fast the stomach empties and improve how the body handles blood sugar. In the SURMOUNT-1 trial, people lost about 15% to 21% of their body weight over 72 weeks, depending on dose. People on placebo lost about 3%.

That matters for more than appearance, because heart and metabolic risk rise after menopause. Some clinics now pair GLP-1 treatment with hormone therapy to address both sides at once. None of this changes the price. But it can change the question from "is this worth it for weight loss" to "is this worth it for my health in this transition."